Hammersmith Hospital

Running trials

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· Source

• Recruiting

  A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing Haemodialysis

  NCT07422532· Source

• Recruiting

  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

  NCT07291076· Phase 1/2· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Source

• Recruiting

  Prospective Evaluation of AI-ECG for SHD Detection

  NCT07057466· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

  NCT06977581· Phase 2· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT06588478· Phase 2· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Source

• Recruiting

  A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

  NCT06500884· Phase 2· Source

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· Source

• Active, not recruiting

  A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06425991· Phase 1· Source

• Active, not recruiting

  A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

  NCT06226571· Phase 1· Source

• Recruiting

  Ablation of Focal Activation in Atrial Fibrillation

  NCT06402617· Source

• Active, not recruiting

  Differentiation of Benign From Malignant Thyroid Nodules Using Diffuse Reflectance Spectroscopy

  NCT07124065· Source

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Source

• Recruiting

  Physiological Versus Right Ventricular Outcome Trial Evaluated for Bradycardia Treatment Upgrades

  NCT06052475· Source

• Recruiting

  Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)

  NCT05967143· Source

• Active, not recruiting

  Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease

  NCT05755711· Source

• Recruiting

  Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  NCT05786924· Phase 1/2· Source

• Recruiting

  The Role of Right Atrial Ectopy Triggering Ganglionated Plexuses in AF

  NCT05539040· Source

• Active, not recruiting

  Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

  NCT05531526· Phase 3· Source

• Recruiting

  Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

  NCT03994471· Phase 3· Source

• Active, not recruiting

  A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

  NCT05455320· Phase 3· Source

• Recruiting

  A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

  NCT05431088· Phase 2/3· Source

• Recruiting

  A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

  NCT05519085· Phase 3· Source

• Recruiting

  Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

  NCT05185739· Phase 2· Source

• Recruiting

  Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

  NCT05254171· Phase 2/3· Source

• Recruiting

  Lutathera and ASTX727 in Neuroendocrine Tumours

  NCT05178693· Phase 1· Source

• Recruiting

  OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.

  NCT04493632· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

  NCT05031780· Phase 2/3· Source

• Recruiting

  A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

  NCT05037760· Phase 2· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

  NCT04712097· Phase 3· Source

• Recruiting

  Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

  NCT04886804· Phase 1· Source

• Active, not recruiting

  A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

  NCT04770896· Phase 3· Source

• Recruiting

  A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

  NCT04710576· Phase 2· Source

• Recruiting

  Methods of T Cell Depletion Trial (MoTD)

  NCT04888741· Phase 2· Source

• Active, not recruiting

  Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT04579367· Source

• Active, not recruiting

  A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04628494· Phase 3· Source

• Active, not recruiting

  A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

  NCT04607421· Phase 3· Source

• Active, not recruiting

  A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

  NCT04217278· Phase 2/3· Source

• Enrolling by invitation

  A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

  NCT03683186· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer4 recruiting
• Multiple myeloma4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Pancreatic cancer3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Atrial fibrillation2 recruiting
• Chronic kidney disease2 recruiting
• Colorectal cancer2 recruiting
• Heart failure2 recruiting
• High blood pressure2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Type 2 diabetes2 recruiting
• Acute myeloid leukemia1 recruiting
• Asthma1 recruiting
• Childhood cancers1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Hodgkin lymphoma1 recruiting
• Lung cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting
• Sickle cell disease1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

  NCT06274801· Phase 3· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· Source

• Terminated

  A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

  NCT06039384· Phase 1· Source

• Completed

  A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

  NCT06137742· Phase 1/2· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Completed

  OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.

  NCT05844566· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Source

• Completed

  A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

  NCT05249426· Phase 1· Source

• Completed

  A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

  NCT04912869· Phase 1· Source

• Completed

  A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

  NCT05075824· Phase 2· Source

• Terminated

  The Long-term Safety and Effect of Renal Denervation

  NCT05818813· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Source

• Completed

  Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

  NCT04173533· Phase 3· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Source

• Completed

  Long Term Extension Trial of Setmelanotide

  NCT03651765· Phase 2/3· Source

• Completed

  Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

  NCT03117933· Phase 2· Source

• Terminated

  Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

  NCT02629692· Phase 1/2· Source

• Completed

  Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

  NCT02101788· Phase 2/3· Source